Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:25 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1602

Shown on this page

Current sort

Live official records

Conditions: Phenylketonurias
Interventions: NGGT002; Genetic
Lead sponsor: NGGT INC.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Orange, California • Minneapolis, Minnesota • Morristown, New Jersey + 2 more

Conditions: Opioid Use Disorder, Chronic Pain
Interventions: Patient-Oriented Dosing (POD), Pain Self-Management (PSM), Usual Care, Standard Buprenorphine Dosing Condition; Drug · Behavioral
Lead sponsor: Erin Winstanley; Other
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Baltimore, Maryland • Dundalk, Maryland • Hagerstown, Maryland + 6 more

Conditions: Attention Deficit/Hyperactivity Disorder(ADHD), Alcohol Use
Interventions: Ecological Momentary Assessment for ADHD and Substance Use - Intervention Group, Ecological Momentary Assessment for ADHD & Substance Use - Control Group; Device
Lead sponsor: Traci Kennedy; Other
Eligibility: 18 Years to 25 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS), Myeloproliferative Neoplasm (MPN)
Interventions: Thiotepa, Fludarabine, Busulfan, PBSC infusion; Drug · Procedure
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Overweight or Obesity, Diabetes Mellitus, Type 2, Physical Inactivity
Interventions: Physical Activity, Delayed intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer Metastatic
Interventions: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Santa Monica, California + 14 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib, Teriflunomide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more

Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions: Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 106
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Arthritis Knee
Interventions: Robotic assisted total knee arthroplasty, Manual total knee arthroplasty, Robotic assisted revision total knee arthroplasty, Manual revision total knee arthroplasty; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years to 90 Years
Enrollment: 30 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
Interventions: Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration; Other · Procedure · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 153
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more

Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions: ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Drug · Procedure · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 22 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Live official records

AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment

Smartphone-based Intervention for Young Adults With ADHD

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

PA Moves Trial - Patient Participants

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Functional Recovery After Total Knee Arthroplasty

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

About this UPMC (University of Pittsburgh) institution page